As the world’s leading hyaluronic acid R&D, production and sales enterprise, BLOOMAGE BIOTECH raw materials business has a strong and stable performance, occupying a big advantage in the market competition. On November 10, 2022, in order to strengthen the supervision and management of medical sodium hyaluronate (sodium hyaluronate) products, National Medical Products Administration of China issued the Announcement of National Medical Products Administration of China on Management Categories of Medical Sodium Hyaluronate Products. According to the different application fields, the Announcement divides the pharmaceutical grade products of hyaluronic acid into three categories: drugs, second-class medical devices and third-class medical devices.
According to industry insiders, after the official announcement, more medical sodium hyaluronate products will be approved in China, which will effectively drive the growth of the raw material market of medical grade sodium hyaluronate, and the market share of leading companies in the industry is expected to further increase.
Relying on the advantages of biological fermentation technology and industrialization, BLOOMAGE BIOTECH’s hyaluronic acid industrialization scale has always been in the forefront of the world. The pharmaceutical grade HyatrueTM sodium hyaluronate produced by it is fermented by Streptococcus zooepidemicus, non-transgenic, non-animal source, natural and safe. Also, it has the characteristics of high purity (impurities such as nucleic acid and protein are far lower than the European Pharmacopoeia standard, and the actual level of endotoxin can even be lower than the detection limit of the method) and high stability.
In addition, BLOOMAGE BIOTECH can accurately customize the molecular weight according to the customer’s needs, and produce HyatrueTM sodium hyaluronate from 3K Da to 3.5 million Da, so as to meet the application requirements of HA in external skin preparation, ophthalmology, cosmetic filling, facial rejuvenation, joint injection and other medicines and medical devices.
BLOOMAGE BIOTECH attaches great importance to the global industrial layout, and its production plants have passed the official on-site inspections such as cGMP of FDA in the United States and GMP of NMPA in China, and registered products in countries including the European Union, the United States, South Korea and Japan. At present, there are more than 600 R&D personnel in BLOOMAGE BIOTECH, and sales subsidiaries are set up in the United States, France, Japan and South Korea, which can provide customers with all-round products, technical services and application solutions.
The fundamental reason why BLOOMAGE BIOTECH can become a leading enterprise in the industry is the pharmaceutical grade HA raw materials and unique advantages. Under the background of accelerating the strategic layout of raw materials business, BLOOMAGE BIOTECH’s international market share of raw materials is also expected to continue to deepen, upgrade and accelerate its development.